Overview
CGEN market data
Price History
CGEN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CGEN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026Benzinga · Jun 18, 2026, 11:15 AM
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026Benzinga · Jun 11, 2026, 11:14 AM
Compugen Q1 2026 Earnings Call: Complete TranscriptBenzinga · Jun 1, 2026, 1:04 PM
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5Benzinga · May 21, 2026, 2:45 PM
Earnings Scheduled For May 18, 2026Benzinga · May 18, 2026, 11:15 AM
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M EstimateBenzinga · May 18, 2026, 11:05 AM